Crescent Biopharma, Inc. (CBIO)

Crescent Biopharma, Inc. (CBIO) Healthcare & Pipeline Overview

Crescent Biopharma, Inc. is a biotechnology firm specializing in cancer therapy research and development, focusing on novel bispecific antibodies like CR-001, CR-002, and CR-003. The company's strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical enhances its capabilities in developing and commercializing oncology therapeutics, positioning it within the competitive biotechnology sector.

What Is the Investment Thesis for CBIO?

Crescent Biopharma, Inc. presents a focused investment opportunity within the biotechnology sector, primarily driven by its pipeline of cancer therapy candidates, including the lead asset CR-001. The strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. provides a collaborative framework for development and commercialization, potentially accelerating the path to market. Key value drivers include successful clinical trial outcomes for CR-001 and subsequent regulatory approvals. However, the company's negative profit margin of -1363.9% indicates substantial ongoing research and development expenses, posing a financial risk. Investors should closely monitor clinical trial progress, partnership milestones, and cash burn rate to assess the company's long-term viability and potential for return on investment. The company's market capitalization stands at $0.60 billion as of May 9, 2026.

Based on FMP financials and quantitative analysis

CBIO Key Highlights

• Crescent Biopharma's pipeline includes CR-001, an anti-PD-1/anti-VEGF bispecific antibody targeting solid tumors, representing a potential breakthrough in cancer therapy.
• The company maintains a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., enhancing its development and commercialization capabilities in oncology.
• Crescent Biopharma's gross margin is 100.0%, indicating efficient management of direct costs associated with its research and development activities.
• The company's market capitalization is $0.60 billion, reflecting investor valuation of its current and future potential.
• Crescent Biopharma employs 41 individuals, indicating a focused and agile operational structure.

Who Are CBIO's Competitors?

CBIO is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are CBIO's Key Strengths?

• Innovative bispecific antibody technology.
• Strategic partnership with Sichuan Kelun-Biotech.
• Focused pipeline of cancer therapy candidates.
• Experienced management team.

What Are CBIO's Weaknesses?

• High research and development costs.
• Dependence on strategic partnerships.
• Limited commercialization experience.
• Negative profit margin.

What Could Drive CBIO Stock Higher?

• Clinical trial results for CR-001 in solid tumors.
• Potential expansion of strategic partnership with Sichuan Kelun-Biotech.
• Regulatory submissions for CR-001.
• Advancement of CR-002 and CR-003 through preclinical and clinical development.

What Are the Key Risks for CBIO?

• Unfavorable clinical trial results for CR-001.
• Regulatory delays or rejection of CR-001.
• Competition from established pharmaceutical companies.
• High research and development costs.
• Patent challenges and intellectual property disputes.

What Are the Growth Opportunities for CBIO?

• Successful Clinical Trials for CR-001: The successful completion of clinical trials for CR-001, Crescent Biopharma's lead anti-PD-1/anti-VEGF bispecific antibody, represents a significant growth opportunity. Positive trial outcomes could lead to regulatory approval and commercialization, potentially capturing a substantial share of the solid tumor treatment market, estimated to reach $200 billion by 2030. This growth is contingent on demonstrating superior efficacy and safety compared to existing therapies, providing a competitive advantage.
• Expansion of Strategic Partnerships: Expanding strategic partnerships with other biotechnology and pharmaceutical companies can provide Crescent Biopharma with access to additional resources, technologies, and market channels. These collaborations can accelerate the development and commercialization of its pipeline assets, reducing risk and increasing the potential for revenue generation. The market for pharmaceutical collaborations is projected to grow to $150 billion by 2028, offering ample opportunities for Crescent Biopharma to forge mutually beneficial alliances.
• Advancement of CR-002 and CR-003: Advancing the development of CR-002 and CR-003, the other assets in Crescent Biopharma's pipeline, represents another key growth opportunity. Successful preclinical and clinical development of these candidates could expand the company's product portfolio and address additional unmet needs in cancer treatment. Each successful drug approval can unlock significant market potential, with peak sales often reaching hundreds of millions or even billions of dollars.
• Geographic Expansion: Expanding into new geographic markets, particularly in Asia and Europe, can drive revenue growth for Crescent Biopharma. These regions offer large patient populations and increasing healthcare spending, creating significant opportunities for commercializing its cancer therapies. The global oncology market is expected to grow rapidly in these regions, driven by rising cancer incidence and improved access to healthcare.
• Combination Therapies: Exploring and developing combination therapies involving CR-001 and other agents represents a promising growth avenue. Combining bispecific antibodies with other immunotherapies or targeted agents can enhance efficacy and overcome resistance mechanisms in cancer treatment. The market for combination therapies is growing rapidly, driven by the increasing recognition of the benefits of personalized and multi-faceted treatment approaches.

What Opportunities Does CBIO Have?

• Successful clinical trial outcomes for CR-001.
• Expansion of strategic partnerships.
• Advancement of CR-002 and CR-003.
• Geographic expansion into new markets.

What Threats Does CBIO Face?

• Regulatory hurdles and approval delays.
• Competition from established pharmaceutical companies.
• Patent challenges and intellectual property disputes.
• Unfavorable clinical trial results.

What Are CBIO's Competitive Advantages?

• Proprietary bispecific antibody technology platform.
• Strategic partnership with Sichuan Kelun-Biotech provides access to resources and expertise.
• Focus on innovative cancer therapies addresses a significant unmet need.

What Does CBIO Do?

Crescent Biopharma, Inc. is a biotechnology company dedicated to the research and development of innovative cancer therapy candidates. The company's pipeline features several promising assets, including CR-001, a proprietary anti-PD-1/anti-VEGF bispecific antibody designed to target solid tumors. Additionally, Crescent Biopharma is developing CR-002 and CR-003 as part of its broader oncology portfolio. Crescent Biopharma has established a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., aimed at the collaborative development and commercialization of oncology therapeutics, including novel combinations. This partnership enhances Crescent Biopharma's capabilities and expands its reach in the oncology market. Headquartered in Waltham, Massachusetts, Crescent Biopharma operates with a focused team of 41 employees, driving its research and development efforts. The company's commitment to innovation and strategic collaborations positions it as a player in the competitive biotechnology landscape, striving to address unmet needs in cancer treatment. Crescent Biopharma's approach combines internal research with external partnerships to accelerate the development and delivery of novel cancer therapies.

What Products and Services Does CBIO Offer?

• Researches and develops cancer therapy candidates.
• Develops proprietary anti-PD-1/anti-VEGF bispecific antibodies to treat solid tumors.
• Focuses on oncology therapeutics, including novel combinations.
• Partners with Sichuan Kelun-Biotech Biopharmaceutical for development and commercialization.
• Aims to address unmet needs in cancer treatment through innovative therapies.

How Does CBIO Make Money?

• Develops and patents novel cancer therapy candidates.
• Out-licenses or co-develops its drug candidates with strategic partners like Sichuan Kelun-Biotech.
• Generates revenue through milestone payments, royalties, and potential future product sales.

What Industry Does CBIO Operate In?

Crescent Biopharma operates within the biotechnology industry, a sector characterized by intense research and development, high regulatory hurdles, and significant growth potential. The oncology therapeutics market is a major segment within biotechnology, driven by the increasing prevalence of cancer and the demand for innovative treatments. Crescent Biopharma's focus on bispecific antibodies and strategic partnerships aligns with industry trends toward targeted therapies and collaborative drug development. The competitive landscape includes both large pharmaceutical companies and smaller biotech firms, all vying for market share in this rapidly evolving field. The global biotechnology market is projected to reach trillions of dollars by 2030, reflecting the immense opportunities and challenges within this sector.

Who Are CBIO's Key Customers?

• Pharmaceutical companies seeking to expand their oncology portfolios.
• Patients with solid tumors who may benefit from novel bispecific antibody therapies.
• Healthcare providers who prescribe and administer cancer treatments.

Crescent Biopharma, Inc. Financial Trajectory

Crescent Biopharma, Inc. (CBIO) reported $1.0M in revenue for Q1 2026, a decline of 90.4% compared to the prior quarter. The company recorded a net loss of $23.3M, with diluted EPS of $-0.70.

Company Profile

Crescent Biopharma, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Waltham, US. The company is led by CEO Joshua T. Brumm. CBIO has traded publicly since 2014.

How Crescent Biopharma, Inc. Is Valued

Crescent Biopharma, Inc. carries a market capitalization of $470.24M, placing it in the small-cap category. Relative to its peer group, CBIO's quantitative score of 22/100 is below the peer average of 76/100.

Key Financial Metrics

Return on assets is -81.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -31.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 13.78 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -30.7%, the inverse of the P/E and a quick read on earnings relative to price.

F-Score 4/9Financial Health

Crescent Biopharma, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 15.65 places it in the safe zone, indicating low near-term bankruptcy risk.

FY2026 estForward Outlook

Wall Street analysts project Crescent Biopharma, Inc. revenue of about $1.8M for fiscal 2026, with EPS near $-3.20. The estimate reflects 6 contributing analysts.

CBIO Financials

CBIO Latest News

CBIO Analyst Consensus

CBIO MoonshotScore

Latest Crescent Biopharma, Inc. Analysis

Crescent Biopharma, Inc. Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources